What’s Next for Seres Therapeutics Incorporated (NASDAQ:MCRB) After Having More Shares Shorted?

February 15, 2018 - By Migdalia James

 What's Next for Seres Therapeutics Incorporated (NASDAQ:MCRB) After Having More Shares Shorted?

The stock of Seres Therapeutics Incorporated (NASDAQ:MCRB) registered an increase of 9.55% in short interest. MCRB’s total short interest was 4.60M shares in February as published by FINRA. Its up 9.55% from 4.20 million shares, reported previously. With 171,100 shares average volume, it will take short sellers 27 days to cover their MCRB’s short positions. The short interest to Seres Therapeutics Incorporated’s float is 26.3%.

The stock increased 3.61% or $0.32 during the last trading session, reaching $9.19. About 76,854 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 64.58% since February 15, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $372.47 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 23 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital with “Outperform” on Friday, August 12. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) earned “Outperform” rating by FBR Capital on Wednesday, March 30. Cantor Fitzgerald maintained Seres Therapeutics, Inc. (NASDAQ:MCRB) on Wednesday, August 30 with “Buy” rating. The rating was initiated by Cowen & Co on Monday, June 6 with “Outperform”. On Thursday, October 12 the stock rating was initiated by Oppenheimer with “Buy”. The rating was initiated by Canaccord Genuity on Wednesday, July 22 with “Buy”. The rating was upgraded by Bank of America to “Buy” on Thursday, October 22. Canaccord Genuity maintained Seres Therapeutics, Inc. (NASDAQ:MCRB) on Monday, June 12 with “Buy” rating. On Friday, July 29 the stock rating was initiated by H.C. Wainwright with “Buy”. As per Tuesday, July 21, the company rating was initiated by Bank of America.

More notable recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Businesswire.com which released: “Seres Therapeutics Awarded Grant from CARB-X to Support Development of …” on November 07, 2017, also Marketwatch.com with their article: “Seres Therapeutics stock drops 19% on clinical trial results” published on October 02, 2017, Businesswire.com published: “Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in …” on December 04, 2017. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) were released by: Streetinsider.com and their article: “Seres Therapeutics (MCRB) Names Eric D. Shaff as COO” published on January 31, 2018 as well as Fool.com‘s news article titled: “Here’s What’s Lifting Seres Therapeutics Inc.’s Stock Price Today” with publication date: March 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: